Vigil Neuroscience Inc (VIGL)
3.95
-0.06
(-1.37%)
USD |
NASDAQ |
Jul 03, 16:00
4.00
+0.05
(+1.27%)
Pre-Market: 08:54
Vigil Neuroscience Research and Development Expense (TTM): 61.43M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 61.43M |
| December 31, 2023 | 60.93M |
| September 30, 2023 | 56.34M |
| June 30, 2023 | 53.72M |
| March 31, 2023 | 50.91M |
| December 31, 2022 | 47.44M |
| Date | Value |
|---|---|
| September 30, 2022 | 44.37M |
| June 30, 2022 | 39.39M |
| March 31, 2022 | 35.94M |
| December 31, 2021 | 32.33M |
| September 30, 2021 | 26.39M |
| June 30, 2021 | 40.84M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
26.39M
Minimum
Sep 2021
61.43M
Maximum
Mar 2024
45.84M
Average
45.91M
Median
Research and Development Expense (TTM) Benchmarks
| Assure Holdings Corp | -- |
| Tonix Pharmaceuticals Holding Corp | 73.01M |
| Savara Inc | 52.33M |
| TG Therapeutics Inc | 93.05M |
| scPharmaceuticals Inc | 12.42M |